Theravance Biopharma, Inc. (NASDAQ:TBPH) Expected to Post Q1 2026 Earnings of $0.29 Per Share

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities researchers at Zacks Research increased their Q1 2026 earnings estimates for shares of Theravance Biopharma in a research note issued on Monday, April 15th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will earn $0.29 per share for the quarter, up from their prior forecast of $0.25. The consensus estimate for Theravance Biopharma's current full-year earnings is ($0.83) per share.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.02). The company had revenue of $17.57 million during the quarter, compared to the consensus estimate of $17.49 million. Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%.

Several other equities research analysts have also recently weighed in on the stock. Evercore ISI cut shares of Theravance Biopharma from an "outperform" rating to an "inline" rating in a research report on Monday, January 8th. BTIG Research began coverage on shares of Theravance Biopharma in a research report on Friday. They issued a "buy" rating and a $21.00 price target for the company.

Theravance Biopharma Price Performance

TBPH stock traded down $0.23 during mid-day trading on Tuesday, reaching $9.69. The company had a trading volume of 472,501 shares, compared to its average volume of 385,747. The company has a market capitalization of $470.55 million, a PE ratio of -9.99 and a beta of 0.36. The firm has a 50 day moving average of $8.96 and a 200 day moving average of $9.66. Theravance Biopharma has a 12 month low of $8.21 and a 12 month high of $12.03.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of TBPH. Gerber LLC acquired a new position in Theravance Biopharma during the 4th quarter valued at approximately $112,000. Wellington Management Group LLP increased its stake in shares of Theravance Biopharma by 68.0% in the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company's stock worth $3,227,000 after acquiring an additional 116,164 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Theravance Biopharma by 6.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 286,291 shares of the biopharmaceutical company's stock worth $3,218,000 after acquiring an additional 16,506 shares during the period. Barclays PLC increased its stake in shares of Theravance Biopharma by 253.9% in the fourth quarter. Barclays PLC now owns 82,357 shares of the biopharmaceutical company's stock worth $925,000 after acquiring an additional 59,088 shares during the period. Finally, Newtyn Management LLC increased its stake in shares of Theravance Biopharma by 3.2% in the fourth quarter. Newtyn Management LLC now owns 1,900,000 shares of the biopharmaceutical company's stock worth $21,356,000 after acquiring an additional 58,440 shares during the period. Hedge funds and other institutional investors own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.